期刊文献+

上海市南汇区18271例脑卒中高危人群重点预防效果评价 被引量:19

Effectiveness of Nao’an Capsule on stroke prevention among high risk population in Nanhui,Shanghai
原文传递
导出
摘要 目的评价脑卒中高危人群脑安胶囊重点预防措施的人群实施效果。方法从上海市南汇区全区696558人群选择≥35岁具有脑卒中危险因素暴露者进行脑血管血液动力学检测,筛选出脑血管血液动力学指标积分值低于70分的脑卒中高危个体18271例作为干预对象。根据知情同意的原则,在同样接受一般干预的基础上,将10313例接受“脑安胶囊”干预者作为重点干预组,另7958例未接受脑安胶囊干预者作为一般干预组。随访监测干预后脑卒中的发病和死亡情况,评价干预策略实施3年后的预防效果。结果重点干预组脑卒中发病率显著低于一般干预组(P<0.01),男性下降53.8%,相对危险度为0.46(0.33~0.64);女性下降58.4%,相对危险度为0.39(0.30~0.50)。多因素分析logistic回归分析显示,被筛选进入方程的因素分别为高血压病史、脑血管血液动力学指标积分值、年龄、性别和脑安胶囊干预,其中脑安胶囊干预的相对危险度为0.41,在诸因素中作用最强。结论干预策略实施3年后,脑安胶囊重点干预组的脑卒中发病率显著低于一般干预组,脑安胶囊干预是高危个体脑卒中发病最强的影响因素。 Objective To evaluate the effectiveness of stroke prevention among high risk population,using Nao’an Capsules. Methods Participants were selected from 696 558 residents in Nanhui, using county of Shanghai city. Individuals aged 35 years old and over with at least one risk factor exposure to stroke, received cerebral vascular hemodynamic examination. 18 271 cases meeting the criteria of cerebral vascular hemodynamic indexes accumulative score below 70 points were defined as individuals with high-risk and targets to receive intervention. According to the willingness of the participants, 10 313 cases received Nao’an Capsules for intensive intervention based on general intervention measures compared to 7958 cases only receiving general intervention. After the implementation of intervention, incidence and mortality rates of stroke and the effectiveness of three-year intervention were studied. Results Incidence of stroke in Nao’an Capsules group was significantly lower than that of the general intervention( P < 0.01 ) with 53.8 % in males and 58.4 % in females. The relative risk( RR ) in two gender groups were 0.46 ( 0.33- 0.64 ) and 0.39 ( 0.30- 0.50 ) respectively. Multiple logistic regression analysis indicated that the history of hypertension, accumulative score of cerebral vascular hemodynamic indexes, age, gender and Nao’an Capsules intervention were the variables selected into the equation and significantly related to stroke. Among the variables, Nao’an Capsule was the strongest factor with a RR of 0.41 . Conclusion Incidence of stroke in Nao’an Capsule intervention group was significantly lower than that in the general intervention group after 3 years of intervention,suggesting that Nao’an Capsule intervention was the strongest factor affecting stroke occurrence in individuals at high-risk.
出处 《中华流行病学杂志》 CAS CSCD 北大核心 2005年第5期335-338,共4页 Chinese Journal of Epidemiology
基金 上海市科研专项资金资助项目 (990 0 5 )
  • 相关文献

参考文献11

  • 1黄久仪,郭佐,沈凤英,杨永举,王艳,樊舜英,杨渤生,林建民,曹奕丰,徐晓斌,冯春红,田文生,王桂清.脑血管血液动力学检测预警卒中的筛检试验评价[J].中华流行病学杂志,2002,23(5):383-386. 被引量:84
  • 2郭佐 王桂清 何广成 等 柳兆荣 主编.脑血管血流动力学参数的主成分分析和脑血管功能的综合评估[A].柳兆荣,主编.生物力学新近展[C].成都:成都科技大学出版社,1996.260-264.
  • 3王桂清,王耀山,等.中国卒中高危人群干预试验效果[J].中华国际医学杂志,2003,3(1):22-24. 被引量:16
  • 4American Heart Association. Primary prevention of ischemic stroke. Circulation,2001,103 : 163-182.
  • 5D'Agostino RB, Wolf PA, Belanger AJ, et al. Stroke risk profile:adjustment for antihypertensive medication: the Framingham Study. Stroke, 1994,25:40-43.
  • 6O' Rourke F, Dean N, Akhtar N, et al. Current and future concepts in stroke prevention. CMAJ, 2004,170 : 1123-1133.
  • 7Hart RG, Halperin JL, McBride R, et al. Aspirin for the primary prevention of stroke and other major vascular events: meta-analysis and hypotheses. Arch Neurol,2000,57 : 326-332.
  • 8Collaboration meta analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Antithrombotic Trialists' Collaboration.BMJ ,2002,324: 71-86.
  • 9Bosch J, Yusuf S, Pogue J, et al. HOPE investigators. Heart outcomes prevention evaluation. Use of ramiprll in preventing stroke: double blind randomized trial. BMJ, 2002,324:699-702.
  • 10Sever PS, Dahlof B, Pouher NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-- Lipid Lowering Arm(ASCOT-LLA) : a muhicentre randomized controlled trial. Lancet,2003,361 : 1149-1158.

二级参考文献5

共引文献92

同被引文献160

引证文献19

二级引证文献76

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部